Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
EVFM Evofem Biosciences
0.189
-0.015-7.33%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
48.6% -115.8591 -110.8% -126.3869 62.59% -109.0987 62.59% -109.0987
Receivable Turnover(T)
56.57% 2.9902 200.76% 3.1078 269.64% 2.1937 269.64% 2.1937
Inventory Turnover(T)
102.88% 0.6138 492.6% 0.642 736.55% 0.5466 736.55% 0.5466
Fixed Assets Turnover(T)
270.39% 1.3874 321.91% 1.0074 870.88% 0.7374 870.88% 0.7374
Total Asset Rate(T)
586.49% 0.1919 525.82% 0.1779 1576.21% 0.1081 1576.21% 0.1081
ROA
-183.11% -348.538% 3.34% -300.007% -31.41% -270.513% -31.41% -270.513%
Efficiency Ratios
ROA 5 Year Average
-- -- -- -- -- -836.901% -- --
Profitability Ratios TTM
Gross Margin
44.2% 67.489% 59.89% 59.482% 1130.12% 50.813% 1130.12% 50.813%
Operating Margin
80.16% -861.663% 84.11% -1324.478% 91.29% -2023.302% 91.29% -2023.302%
Net Margin
58.76% -1816.040% 84.55% -1686.190% 92.16% -2501.686% 92.16% -2501.686%
EBITDA Margin
80.23% -8.548% 84.17% -13.1488% 91.32% -20.1089% 91.32% -20.1089%
R & D Expense Ratio
-70.03% 228.010% -75.39% 318.330% -89.49% 401.860% -89.49% 401.860%
Sales Expense Ratio
-81.74% 516.430% -83.6% 836.980% -89.16% 1372.540% -89.16% 1372.540%
Administration Expense Rate
-76.95% 184.700% -88.42% 228.650% -95.56% 299.720% -95.56% 299.720%
Financial Health Ratios
Current Ratio
-88.73% 0.1578 -86.97% 0.1383 -- 0.2189 -- --
Quick Ratio
-86.04% 0.1024 -92.71% 0.0465 -- 0.103 -- --
GrowthRatios
Growth Ratios
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
CEO: Pelletier, Saundra
Market: Pink Market
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top